Scilex Holding Co SCLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SCLX is a good fit for your portfolio.
News
-
Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering
-
Scilex Holding Company Announces $15 Million Registered Direct Offering
-
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
-
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
-
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
-
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
-
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
-
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®
Trading Information
- Previous Close Price
- $0.88
- Day Range
- $0.86–0.94
- 52-Week Range
- $0.80–8.37
- Bid/Ask
- $0.91 / $0.91
- Market Cap
- $96.58 Mil
- Volume/Avg
- 217,599 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.45
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Growth
- Total Number of Employees
- 105
- Website
- https://www.scilexholding.com
Comparables
Valuation
|
Metric
|
SCLX
|
VADP
|
PBAJ
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | — | — |
Price/Sales | 2.45 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
SCLX
VADP
PBAJ
Financial Strength
|
Metric
|
SCLX
|
VADP
|
PBAJ
|
|---|---|---|---|
Quick Ratio | 0.15 | 0.27 | 0.00 |
Current Ratio | 0.19 | 0.38 | 0.00 |
Interest Coverage | −106.04 | −2.67 | −117.73 |
Quick Ratio
SCLX
VADP
PBAJ
Profitability
|
Metric
|
SCLX
|
VADP
|
PBAJ
|
|---|---|---|---|
Return on Assets (Normalized) | −106.47% | −128.37% | −26,648.89% |
Return on Equity (Normalized) | — | — | — |
Return on Invested Capital (Normalized) | −1,960.39% | — | — |
Return on Assets
SCLX
VADP
PBAJ
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Bxmmdcrn | Gsc | $697.4 Bil | |
JNJ
| Johnson & Johnson | Ygqybgql | Prvh | $353.8 Bil | |
MRK
| Merck & Co Inc | Bvmhsfzj | Szrn | $332.3 Bil | |
ABBV
| AbbVie Inc | Syyjjnwj | Nyyw | $282.6 Bil | |
AZN
| AstraZeneca PLC ADR | Fdbjjjsjn | Tpy | $232.3 Bil | |
NVS
| Novartis AG ADR | Dmyjkky | Vmfg | $200.1 Bil | |
RHHBY
| Roche Holding AG ADR | Gbvwhzgdl | Cpsp | $195.3 Bil | |
AMGN
| Amgen Inc | Mgnnssrrpx | Pqfw | $144.5 Bil | |
PFE
| Pfizer Inc | Vmkqzbcyk | Xxrv | $143.8 Bil | |
SNY
| Sanofi SA ADR | Bvdnxcvd | Tlxt | $122.2 Bil |